Novel opportunities for CFTR-targeting drug development using organoids

Johanna F Dekkers¹,², Cornelis K van der Ent¹, and Jeffrey M Beekman¹,²,*
¹Department of Pediatric Pulmonology; University Medical Center Utrecht; Children’s Hospital; Utrecht, the Netherlands; ²Department of Immunology; University Medical Center Utrecht; Children’s Hospital; Utrecht, the Netherlands

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead to production of non-functional CFTR, reduced amounts of normal functioning CFTR or misfolded CFTR with defects in trafficking or function. For decades, CF treatment has been focused on the symptoms of CF, but pharmacotherapy using small molecules that target the basic defect of CF, the mutant CFTR protein, is now possible for a limited amount of subjects with CF. This raises the exciting possibility that the majority of people with CF may receive effective treatment targeting the different CFTR mutants in the future. We recently described a functional CFTR assay using rectal biopsies from subjects with CF that were cultured in vitro into self-organizing mini-guts or organoids. We here describe how this model may assist in the discovery of new CFTR-targeting drugs, the subjects that may benefit from these drugs, and the mechanisms underlying variability in CFTR genotype-phenotype relations.

Introduction

Cystic fibrosis (CF) is a life-shortening autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes an apically expressed anion channel essential for fluid and electrolyte homeostasis of many mucosal surfaces. Subjects with CF display severe pulmonary and gastrointestinal dysfunctions and have a life expectancy of approximately 40 y.

Since the cloning of the CFTR gene 24 y ago, over 1900 mutations have been identified (http://www.genet.sickkids.on.ca). Based on the mechanism by which mutations affect the CFTR protein, they can be classified into 6 groups: (1) no synthesis, (2) defective protein folding and trafficking, (3) defective channel regulation (gating), (4) reduced Cl conductance, (5) reduced amounts of normal functioning apical protein (e.g., by altered splicing) or (6) an increased plasma membrane turnover. F508del is the most dominant CFTR mutation (~67% of all mutant alleles worldwide) expressed by approximately 90% of subjects with CF (http://www.genet.sickkids.on.ca/). Multiple co- and post-translational folding steps are affected in CFTR-F508del causing retention at the endoplasmic reticulum, rapid degradation and severely reduced expression at the apical membrane. At the apical membrane CFTR-F508del further shows defects in gating and plasma membrane retention. Due to the high prevalence of CFTR-F508del in the CF population, it is the prime target for CFTR-directed pharmacotherapy.

Pharmacotherapy of CFTR

Pharmacotherapy using small molecules that target CFTR mutants is an exciting new possibility to treat CF. Effective restoration of mutant CFTR by compounds depends on the defect associated with the CFTR mutation. In addition, it is expected that other subject-specific factors impact the efficacy of the pharmacotherapy as observed for many
established drugs. Thus far, the CFTR potentiator Kalydeco (VX-770) is the only CFTR-targeting drug commercially available and it is approved for a select subset of CF subjects (< 4%) expressing the gating mutant CFTR-G551D. This exciting development demonstrates that CFTR-directed pharmacotherapy is feasible, and may possibly be designed for the majority of subjects with CF.

Preclinical and clinical data indicate that robust restoration of CFTR-F508del requires a combination of compounds that both target the folding defect (correctors) and the gating defect (potentiators). Results from a phase II clinical trial with the corrector Lumacaftor (VX-809) and the potentiator Kalydeco (VX-770) indicated that absolute lung function significantly improved by 6.7% in subjects homozygous for CFTR-F508del (http://investors.vrtx.com/releasedetail.cfm?releaseid=687394). In this trial, treatment effects were observed in over 50% of the subjects, and approximately 25% of the subjects demonstrated 10% lung function increase, and a phase III clinical trial has been initiated for CFTR-F508del homozygous patients. This approach is likely not sufficient to “cure” CF in these subjects, indicating that discovery of novel CFTR-restoring compounds is important.

Lung function improvement in the subjects with a single CFTR-F508del allele was lower and likely relates to the lower expression of Lumacaftor and Kalydeco-responsive mutant CFTR protein. Although the effects for this group as a whole were limited, it could very well be that individual patients may respond to the treatment. Identification of these subjects is important to ensure that subjects who may benefit from potential treatments are not missed, and receive treatment as quickly as possible.

**Prediction of Individual CFTR-Restoring Drug Efficacy by Functional Models**

The efficacy of CFTR-restoring pharmacotherapy may be predicted ex vivo or in vitro by patient-specific CFTR function measurements. Various methods may have the potential to predict in vivo drug efficacy, and these approaches will likely complement each other. Ex vivo rectal biopsies have been used to study the modulation of CFTR function and the strength of this method is both with its direct relation to the patient and the sensitivity to measure CFTR function. However, only a limited amount of biopsies (4–8) can be isolated from one patient, so only a small patient-specific data set can be generated. In vitro primary airway cell cultures can be generated in large numbers from lung explants, but cultures set up from patients that can mostly benefit from treatment require invasive procedures and are limited due to loss of differentiation potential upon passaging of basal cells. In addition, the measurement of CFTR function using this method is time consuming. Recently, progress has been reported in differentiating induced progenitor stem cells (iPSC) into airway cells. This approach generates a limitless supply of patient-specific cells, but technical advances are further needed to ensure genomic integrity of iPSC clones and optimal airway differentiation protocols.

We developed a novel functional CFTR assay using intestinal adult stem cell cultures generated from rectal biopsies after intestinal current measurements. Compared with the other available patient-specific models, analysis of CFTR-function in these “organoid” cultures is fast, robust, and accurate and allows for the generation of large data sets from individual subjects within several weeks after isolation. Furthermore, these cultures are (epi)genetically stable and can be stored in liquid nitrogen, features that are essential for biobanking and high-throughput screening. The potential weakness of these cultures is due to the intestinal origin of the cells; responses of intestinal cells may not fully represent responses of airway cells.

**A Novel Functional CFTR Assay in Intestinal Organoids from CF Subjects**

We typically start intestinal organoid cultures from rectal biopsies used for diagnostic purposes of CF. Crypts isolated from biopsies are cultured in a three dimensional matrix and self-organize into
mini-guts or organoids that recapitulate essential features of the in vivo tissue architecture. These pure epithelial cultures consist of closed single epithelial layers with the apical membrane facing a central lumen, and multiple crypt domains that harbor the stem cells. A repetitive culture cycle including organoid expansion for 7 d, mechanical disruption into single crypts and passaging to new wells allows for the generation of large amounts of material that can be used for functional CFTR measurements or liquid nitrogen storage (Fig. 1).

Chemical activation of CFTR by forskolin or cholera toxin rapidly leads to volumetric expansion or swelling of the organoids due to accumulation of fluid in the organoid lumen, a process that is fully CFTR-dependent. To quantify forskolin-induced swelling (FIS), organoids from a 7 d-old culture are passaged into 96-well plates. After 24 h of culturing (with or without CFTR correctors), organoids are labeled with calcein green, stimulated with forskolin (with or without CFTR potentiators) and directly imaged by confocal microscopy (Fig. 2A). We observed that FIS was absent in organoids derived from Cftr−/− mice or in human organoids with CFTR null alleles, reduced in organoids expressing mild CFTR mutations and strongly reduced in organoids expressing severe CFTR mutations. Importantly, FIS of CF organoids was restored by treatment of CFTR-restoring compounds (Fig. 2B).

We here focus on the implications of CFTR function measurements in these organoids for CFTR-targeting drug development. This model can help to address important questions, including (1) what mechanisms control CFTR genotype-phenotype relations and drug efficacy, (2) can novel CFTR-targeting compounds be developed that restore mutant CFTR function for the majority of subjects with CF?, and (3) can patient-specific in vitro models complement CFTR-genotyping for the stratification of CF patients and CFTR-targeting drugs?

Organoids to Study Genotype-Phenotype Relations in CF

Genetic variation in CFTR and other modifier genes are important for CF disease progression. FIS of organoids can reveal important relations between genotype and CFTR residual function of individual subjects and how these relate to clinical disease progression, allowing for the identification of mechanisms controlling variability among patients. FIS varied greatly between organoids derived from different CF subjects, and was largest in organoids from patients with milder CF that express CFTR-A455E. We detected FIS in all organoids expressing CFTR-F508del, also when it was expressed from just a single allele. This indicates that the CFTR-F508del allele clearly confers detectable residual function, albeit very limited compared with wild-type function.

Interestingly, we also detected significant differences in FIS between organoids

---

**Figure 2.** CFTR function measurements using intestinal organoids. **(A)** Schematic representation of the method to measure forskolin-induced organoid swelling. **(B)** Confocal images of calcein-green labeled F508del/F508del organoids with or without VX-809 + VX-770 treatment at the indicated time points of forskolin stimulation.
from **CFTR-F508del** homozygous subjects, and differences in FIS were stable upon propagation of organoids in culture for at least seven weeks. This indicates that cell-intrinsic mechanisms play a role in controlling individual CFTR-F508del function, and are likely conferred by genetic variability between subjects. These clear phenotypic differences between **CFTR-F508del** subjects, and the ability to grow large quantities of pure individual epithelium will be important to define cellular mechanisms or molecular and genetic factors associated with residual function.

The variations in the low levels of residual function that we observed in **CFTR-F508del** homozygous organoids can be clinically relevant as subjects expressing two class I **CFTR** alleles (no functional CFTR) have reduced lung function compared with subjects with two class II alleles such as **CFTR-F508del**.\(^{25,26}\) Correlations between clinical disease phenotype and FIS measurements in both cross-sectional and longitudinal studies are required to assess whether subject-specific FIS in organoids is predictive of lung disease progression in **CFTR-F508del** homozygous subjects. If so, pharmacological targeting of mechanisms that control **CFTR-F508del** residual function may be important to improve function of mutant CFTR, and possibly efficacy of CFTR-targeting drugs.

**CF Organoids for Development of CFTR-Targeting Drugs**

The functional CFTR assay in organoids also offers new opportunities for identification of novel CFTR-targeting drugs. The complete dependency of CFTR and robustness of response allow accurate measurements of CFTR function with an excellent signal-to-noise ratio. The simple experimental set up and readout, as well as the capacity to expand cells into large volumes, are all mandatory for high throughput approaches.

Together with Prof GL Lukacs, we recently demonstrated that compounds targeting distinct sites within **CFTR-F508del** synergize with VX-809 to correct the folding defect.\(^{27}\) This indicates that organoids can be used for identification of novel therapeutic combinations that restore CFTR function. In addition, we successfully used CFTR inhibitors in wild-type CFTR-expressing organoids and showed that other stimuli, such as cholera toxin, could also strongly induce swelling. This points out that potential compounds that inhibit secretory diarrhea may be identified using variations of the swell assay.

In vitro primary airway epithelial cell cultures play an important role for pre-clinical validation of compounds that modulate mutant CFTR. Thus far, the observations in organoid cultures appear to resemble responses of airway cultures to CFTR-targeting drugs.\(^{6,10}\) We found similar dose-dependencies to VX-809 and VX-770, and a similar hierarchy of CFTR-restoring efficacy of VX-809, VX-770, Corr-4a, and VRT-325. Although the responses to CFTR-restoring drugs are similar between **CFTR-F508del** airway cultures and organoids, we observed that the relation of responses with wild-type cultures was approximately 2-fold higher in organoids. This likely reflects different relations between CFTR protein function and culture-specific functional readouts.

Together, this indicates that agonist-induced swell assays in organoids are a suited platform for identification of CFTR-targeting drugs, either as a primary screening model or for preclinical validation of previously identified hits.

**Organoids for Stratification of CF Subjects**

Stratification of subjects for drugs is important to maximize the effective use of therapeutics. As discussed above, clinical trials with CFTR-targeting drugs indicate that these drugs have variable efficacy among individuals, as has been observed for most drugs.\(^{5}\) Especially when treatment efficacy is uncertain for individuals, and when high costs limit empirical approaches for application of drugs, stratification of patients for drugs becomes more important.

Ideal stratification methods should have high sensitivity (fraction of identified true drug-responsive subjects) to identify as much subjects as possible that will benefit from treatment. The specificity of such methods (fraction of identified true non-responsive subjects) is important to limit the risk of potential off-target effects without beneficial therapeutic effects, and to limit the economical burden associated with ineffective treatment. The identification of non-responding subjects becomes more important when multiple treatment options are available and CF disease progresses due to ineffective treatment. As there is only a single CFTR-targeting drug registered at this moment, the main goal for now is to develop methods that have maximal sensitivity.

It is crucial to include subjects that will respond to drugs in clinical trials to demonstrate clinical efficacy. Currently, inclusion of subjects for clinical trials for CFTR-restoring drugs depends mostly on defining **CFTR** genotypes (or classes) that have been shown to react to drugs in vitro, in combination with specific inclusion and exclusion criteria based on individual clinical disease parameters. In this way, CFTR-targeting drugs can be registered for subgroups of patients expressing particular **CFTR** genotypes, and this cycle can be repeated to demonstrate therapeutic efficacy for other genotypes. This model was successfully applied to register Kalydeco for **CFTR-G551D**-expressing subjects, and currently novel genotypes are being selected for Kalydeco treatment.\(^{28}\)

Especially for subjects expressing complex or rare **CFTR** genotypes, in vitro replication of **CFTR** mutations in ectopic expression models can be difficult (e.g., for splice site mutations). In addition, clinical trials are difficult to perform in subjects with rare genotypes with sufficient power to demonstrate efficacy. This indicates that prediction and in vivo validation of individual responses to CFTR-targeting drugs is important for selection of subjects for drugs that have originally been registered for other genotypes. We found different responses to CFTR-targeting drugs in organoids from subjects with various **CFTR** genotypes suggesting that this model can be useful to select drug-responsive **CFTR** genotypes.\(^{17}\)

In addition, individual measurements that predict efficacy of drugs can be important to select responding subjects independent of CF-causing mutation. We and others found that CFTR protein
expression and function can be different for subjects harboring two CFTR-F508del alleles, as can be their response to CFTR-targeting drugs.\(^6,7,12,17,19,30\)

In organoids, subject-specific drug profiles are stable at multiple culture time points, indicating that cell-intrinsic mechanisms, independent of the CF-causing mutations, further control efficacy of CFTR-restoring drugs. Interestingly, Flume et al. found that sweat chloride levels decreased ≥ 10 mmol/L in approximately 15% of CFTR-F508del homozygous patients upon Kalydeco treatment, suggesting that some homozygous CFTR-F508del individuals may already benefit from potentiator therapy.\(^3\)

This supports that polymorphisms within CFTR itself, efficacy of transcription, translation, and/or post-translational processing of CFTR-F508del are different between individuals, which can affect in vivo efficacy of CFTR-targeting drugs.

A clear advantage of the organoid-based FIS measurements is the relatively rapid and detailed analysis of subject-specific efficacy of CFTR-modulating agents. Organoid cultures can be biobanked to ensure that material is stored after a single isolation procedure for current and future drug testing. Experiences from our own clinical center and others have indicated that procedures to isolate rectal biopsies are well tolerated by subjects, although repeated isolations of biopsies are less well tolerated.\(^12,31,32\)

In conclusion, organoids can be cultured from individual subjects without highly invasive procedures, and can play an important role in stratifying subjects for CFTR-restoring drugs. The main advantage of organoid-based stratification over current genetic approaches is that organoid-based measurements also integrate individual factors that interact with the CFTR gene and the CFTR protein and play a role in the efficacy of CFTR-restoring drugs at the level of the individual. A personalized medicine approach for CF may be developed by identifying the most optimal combinations of CFTR-restoring drugs for an individual using the FIS assay when more drugs are registered in the future. For now, FIS in organoids can be important to select individuals (and CFTR-genotypes) for Kalydeco treatment. In addition, individual drug measurements in organoids may play a role in clinical trials with CFTR-restoring drugs to identify responsive individuals. Future direct studies should point out whether responses in organoids are predictive of in vivo drug efficacy.

**Final Remarks**

In the past decades, tremendous progress has been achieved in the treatment of CF. Targeting the mutant CFTR protein has been proven effective for a limited number of patients, and has ignited an enormous effort by academia and industry to develop CFTR-targeting pharmacotherapy for the majority of CF subjects. Still, robust functional restoration of CFTR-F508del by pharmacotherapy has been proven difficult, and it is likely that a variety of compounds are needed to treat CF effectively in the majority of patients.

We developed a novel functional CFTR assay in organoid cultures grown from rectal biopsies from CF patients. These stem cell-cultures self-organize into mini-guts in vitro and can be greatly expanded and biobanked. CFTR function measurements in this model are highly accurate and sensitive, and offer new opportunities for CFTR-targeting drug discovery and patient stratification for CFTR-targeting drugs. These cultures are also especially suited to study functional interactions between genotype, phenotype, and CFTR-restoring drugs, and the mechanisms that define these interactions at the level of individual subjects.

**Disclosure of Potential Conflicts of Interest**

No potential conflict of interest was disclosed.

---

**References**

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992-2001; PMID:15888700; http://dx.doi.org/10.1056/NEJMra043384

2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielinski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-73; PMID:2475911; http://dx.doi.org/10.1126/science.2475911

3. Zielinski J. Genotype and phenotype in cystic fibrosis. Respiratoin 2000; 67:117-33; PMID:10773783; http://dx.doi.org/10.1159/000029497

4. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Respiration 2000; 67:117-33; PMID:10773783; http://dx.doi.org/10.1159/000029497

5. Sondel P, Needleman P, Prockop DJ, et al. Isolation of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-73; PMID:2475911; http://dx.doi.org/10.1126/science.2475911

6. Rowan SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992-2001; PMID:15888700; http://dx.doi.org/10.1056/NEJMra043384

7. Ramsey BW, Davies J, McElvaney NG, Tulliu E, Bell SC, Drevins P, Greise M, McKone EF, Wainwright CE, Konstan MW, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663-72; PMID:22047575; http://dx.doi.org/10.1056/NEJMoa1105185

8. Clancy JP, Rowe SM, Accurso FJ, Arken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. Results of a phase IIA study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67:12-8; PMID:21825083; http://dx.doi.org/10.1136/thoraxjnl-2011-200593

9. Flume PA, Lioni TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE; VX08-770-102 Study Group. A CFTR corrector compound, VX-809, improves the F508del-CFTR mutation. Thorax 2012; 67:12-8; PMID:21825083; http://dx.doi.org/10.1136/thoraxjnl-2011-200393

10. Roth EK, Herrt S, Duerr J, Wenning D, Eichler I, Seydewitz I, Aner MD, Mall MA. The K-channel opener 1-EBO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS One 2011; 6:e24445; PMID:21909392; http://dx.doi.org/10.1371/journal. pone.0024445

11. Derichs N, Sams J, Von Kanel T, Stolpe C, Zapf A, Tummler B, Gallati S, Ballmann M. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010; 65:594-9; PMID:20627915; http://dx.doi.org/10.1136/thx.2009.125088

12. Karp PH, Moninger TO, Weber SP, Nesselhauf TS, Launspach JL, Zabner J, Welsh MJ. An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures. Methods Mol Biol 2002; 188:115-37; PMID:11987537

13. Neuberger T, Burron B, Clark H, Van Goo F. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the preclinical testing of CFTR modulators. Methods Mol Biol 2011; 741:39-54; PMID:21954777; http://dx.doi.org/10.1007/978-1-60779-117-8_4
15. Wong AP, Bear CE, Chio S, Pasceri P, Thompson TO, Huan LJ, Ratjen F, Ellis J, Rossant J. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol 2012; 30:876-82; PMID:22922672; http://dx.doi.org/10.1038/nbt.2328

16. Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell 2013; 13:149-59; PMID:23910082; http://dx.doi.org/10.1016/j.stem.2013.07.001

17. Dekkers JF, Wieringer CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19:939-45; PMID:23727931; http://dx.doi.org/10.1038/nm.3201

18. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 2013; 340:1190-4; PMID:23749498; http://dx.doi.org/10.1126/science.1234852

19. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459:262-5; PMID:19329995; http://dx.doi.org/10.1038/nature07935

20. Sato T, Stange DE, Ferrante M, Vries RG, van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Goor J, Siersma PD, et al. Long-term expansion of epithelial organoids from human colon adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 2011; 141:1762-72; PMID:21889923; http://dx.doi.org/10.1053/j.gastro.2011.07.050

21. Tsui L-C. The spectrum of cystic fibrosis mutations. Trends Genet 1992; 8:392-8; PMID:1279852

22. Vancloey LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007; 175:1636-43; PMID:17332481; http://dx.doi.org/10.1164/rccm.200608-1164OC

23. Weiller CA, Drumm ML. Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol 2013.

24. Gan KH, Veeze HJ, van den Ouweland AM, Halley DJ, Scheffer H, van der Hout A, Overbeek SE, de Jonge HC, Bakker W, Heijerman HG. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995; 333:95-9; PMID:7599891; http://dx.doi.org/10.1056/NEJM199507133330204

25. Cleveland RH, Zurakowski D, Slaterley D, Colin AA. Cystic fibrosis genotype and assessing rates of decline in pulmonary status. Radiology 2009; 253:813-21; PMID:19952026; http://dx.doi.org/10.1148/radiol.2533090418

26. Geborek A, Hjelte L. Association between genotype and pulmonary phenotype in cystic fibrosis patients with severe mutations. J Cyst Fibros 2011; 10:187-92; PMID:21554377; http://dx.doi.org/10.1016/j.jcf.2011.01.005

27. Okizono T, Vezin G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 2013; 9:444-54; PMID:23666117; http://dx.doi.org/10.1038/nchembio.1253

28. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr., Urrutia A, Joubert J, Seegers A, Sussky K, et al. Icacafor potentiating of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11:237-45; PMID:22293084; http://dx.doi.org/10.1016/j.jcf.2011.12.005

29. van Meegen MA, Terheggen-Lagro SWJ, Kovmans KJ, van der Emt CK, Beekman JM. Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis. PLoS One 2013; 8:e57617; PMID:23483918; http://dx.doi.org/10.1371/journal.pone.0057617

30. Penque D, Mendes F, Beck S, Farinha P, Pacheco P, Nogueira P, Lavinha J, Malhô R, Amaral MD. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest 2008; 80:857-68; PMID:10879757; http://dx.doi.org/10.1038/labinvest.3780890

31. De Boeck K, Derichs N, Fajac I, de Jonge HR, Bronsveld I, Sermet I, Vermeulen F, Sheppard DN, Cappens H, Hog M, et al.; ECFS Diagnostic Network Working Group; EuroCareCF WP3 Group on CF diagnosis. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011; 10(Suppl 2):S55-66; PMID:21658643; http://dx.doi.org/10.1016/j.jcf.2011.05.007

32. Servidoni MF, Sousa M, Vinagre AM, Cardoso SR, Ribeiro MA, Meirelles LR, de Carvalho RB, Kunzelmann K, Ribeiro AF, Ribeiro JD, et al. Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trial feasibility. BMC Gastroenterol 2013; 13:91; PMID:23688510; http://dx.doi.org/10.1186/1471-230X-13-91